Acute Myeloid Leukemia (AML) is a type of bone marrow and blood cancer that progresses very quickly when left untreated. AML can occur when the DNA of a developing stem cell of the bone gets damaged, which is known as an acquired mutation. These acquired mutations then become leukemic cells and begin to multiply into multiple cell clusters called leukemia blasts. Leukemia blasts block the production of normal cells and can then grow and survive better than normal cells, which causes the number of healthy red and white blood cells and platelets to be lower than normal. This condition can lead to Anemia, which is a low red blood cell count condition that causes fatigue or shortness of breath, neutropenia, which is caused by a low white blood cell count and lowers the immune system, thrombocytopenia, which is a low platelet count condition that cause bleeding and easy bruising, and pancytopenia, a condition caused by a low count of all healthy blood cells at once.
There are many current therapies out there to treat and even cure AML. Besides standard care, there are also clinical trials available where medical experts conduct research on procedure practices, treatment combinations and new drugs in order to improve the care of current and future AML patients.